Your browser doesn't support javascript.
loading
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba, Rohit; Noureddin, Mazen; Kowdley, Kris V; Kohli, Anita; Sheikh, Aasim; Neff, Guy; Bhandari, Bal Raj; Gunn, Nadege; Caldwell, Stephen H; Goodman, Zachary; Wapinski, Ilan; Resnick, Murray; Beck, Andrew H; Ding, Dora; Jia, Catherine; Chuang, Jen-Chieh; Huss, Ryan S; Chung, Chuhan; Subramanian, G Mani; Myers, Robert P; Patel, Keyur; Borg, Brian B; Ghalib, Reem; Kabler, Heidi; Poulos, John; Younes, Ziad; Elkhashab, Magdy; Hassanein, Tarek; Iyer, Rajalakshmi; Ruane, Peter; Shiffman, Mitchell L; Strasser, Simone; Wong, Vincent Wai-Sun; Alkhouri, Naim.
Afiliação
  • Loomba R; NAFLD Research CenterUniversity of California at San DiegoLa JollaCA.
  • Noureddin M; Fatty Liver ProgramCedars-Sinai Medical CenterLos AngelesCA.
  • Kowdley KV; Liver Institute NorthwestSeattleWA.
  • Kohli A; Arizona Liver HealthChandlerAZ.
  • Sheikh A; GI Specialists of GeorgiaMariettaGA.
  • Neff G; Covenant Research, LLCSarasotaFL.
  • Bhandari BR; Delta Research Partners, LLCBastropLA.
  • Gunn N; Pinnacle Clinical ResearchAustinTX.
  • Caldwell SH; University of VirginiaCharlottesvilleVA.
  • Goodman Z; Inova Fairfax HospitalFalls ChurchVA.
  • Wapinski I; PathAIBostonMA.
  • Resnick M; PathAIBostonMA.
  • Beck AH; PathAIBostonMA.
  • Ding D; Gilead Sciences Inc.Foster CityCA.
  • Jia C; Gilead Sciences Inc.Foster CityCA.
  • Chuang JC; Gilead Sciences Inc.Foster CityCA.
  • Huss RS; Gilead Sciences Inc.Foster CityCA.
  • Chung C; Gilead Sciences Inc.Foster CityCA.
  • Subramanian GM; Gilead Sciences Inc.Foster CityCA.
  • Myers RP; Gilead Sciences Inc.Foster CityCA.
  • Patel K; University of TorontoTorontoOntarioCanada.
  • Borg BB; Southern Therapy and Advanced ResearchJacksonMS.
  • Ghalib R; Texas Clinical Research InstituteArlingtonTX.
  • Kabler H; Jubilee Clinical ResearchLas VegasNV.
  • Poulos J; Cumberland Research AssociatesFayettevilleNC.
  • Younes Z; Gastro OneGermantownTN.
  • Elkhashab M; Toronto Liver CentreTorontoOntarioCanada.
  • Hassanein T; Southern California Research CenterCoronadoCA.
  • Iyer R; Iowa Digestive Disease CenterCliveIA.
  • Ruane P; Ruane Medical and Liver Health InstituteLos AngelesCA.
  • Shiffman ML; Bon Secours Mercy HealthRichmondVA.
  • Strasser S; Royal Prince Alfred Hospital and The University of SydneyCamperdownNew South WalesAustralia.
  • Wong VW; Department of Medicine and TherapeuticsThe Chinese University of Hong KongHong KongHong Kong.
  • Alkhouri N; Texas Liver InstituteUT Health San AntonioSan AntonioTX.
Hepatology ; 73(2): 625-643, 2021 02.
Article em En | MEDLINE | ID: mdl-33169409
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Pirimidinas / Azetidinas / Doença Hepática Terminal / Isobutiratos / Hepatopatia Gordurosa não Alcoólica / Ácidos Isonicotínicos / Cirrose Hepática Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Pirimidinas / Azetidinas / Doença Hepática Terminal / Isobutiratos / Hepatopatia Gordurosa não Alcoólica / Ácidos Isonicotínicos / Cirrose Hepática Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article